Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency which causes an impairment of the mitochondria1 ,!?-oxidation of medium-chain fatty acids, is one of the more commonly diagnosed inborn errors of metabolism [l]. The Abbreviations used: MCAD, medium-chain acyl-CoA dehydrogenase; TMAO, trimethylamine-N-oxide; TSW,. 3-trimethylsilyl-2,2,3,3-tetradeuteropropionate.
disorder presents as a non-ketotic hypoglycaemia associated with reduced plasma carnitine levels resembling Reye's syndrome [ 2 ] . The disorder is characterized by the detection of urinary dicarboxylic and hydroxyacids derived from ooxidation and w -1 -oxidation, respectively, of the accumulating parent monocarboxylic acids [3] and by the excretion of acylglycine (suberylglycine or hexanoylglycine) and acylcarnitine (octanoylcarnitine or hexanoylcarnitine) conjugates which appear to be exclusive to this disorder and could serve as specific diagnostic markers [4] .
Previous work has shown the value of utilizing 'H-n.m.r. for diagnosis and therapeutic monitoring in several inherited disorders (5, 61. The present study involved following the urinary metabolite pattern from an MCAD-deficient patient, both during a fat challenge in the form of long-chain triacylglycerol and after L-carnitine administration. Legend: Adp, adipic acid; Cit, citrate; Cr, creatine; Crn, creatinine; DMA, dimethylamine; Gly, glycine; HG, hexanoylglycine; 30HB, 3 hydroxybutyrate; 50HH. 5 hydroxyhexanoic acid; OC, octanylcarnitine; SEB, sebacic acid; Sub, suberic acid; SG, suberylglycine; SUC, succinate. 
and chemical shift reference, respectively. Analyses were carried out on either a Bruker WM400 or Jeol GSX500 spectrometer using a single-pulse sequence with gated irradiation of the residual water signal or the Hahn spin-echo pulse sequence (YO 7-180 7-acquire), where 7 = 60 ms.
Challenging the patient with fat resulted in an immediate increased excretion of derivatives of urinary medium-chain fatty acid (Fig. la) . Dicarboxylic acids (adipic, suberic and sebacic), usually undetectable while the patient was in a stable condition, were excreted in substantial amounts (up to 1 mol/mol creatinine), while hexanoylglycine and octanoylcarnitine excretion, which we have found to be constant under basal conditions, were more than doubled.
The elevation in octanylcarnitine excretion suggests that elimination o f octanoyl-CoA by truns-esterification with carnitine via acyl transferases may cause a depletion in cellular carnitine stores. Administration of L-carnitine as an oral bolus dose (200 mg/kg body weight) was associated with a diminution of acylglycine excretion, while almost 50"h of carnitine recovered in the urine was in the form of acetyland octanoyl-conjugates (Fig. I h) . Use of carnitine supplements during metabolic perturbation would result in the liberation of free CoA for other key metabolic reactions; however, under basal conditions, when the patient is metabolically well, carnitine administration could be contraindicated, since this could increase the transfer of long-chain fatty acyl-CoAs into the mitochondria exerting stress on the defective medium-chain B-oxidation pathway.
An additional novel finding was the detection of a large increase in urinary trimethylamine-N-oxide (TMAO) concentration subsequent to carnitine administration. These findings have been substantiated in two other cases of MCAD deficiency, where TMAO levels were elevated above normal after carnitine treatment. We believe this may be a result of carnitine degradation by intestinal micro-organisms [ 71 and may be a major route of carnitine loss during therapy in some metabolic disorders.
